隨著人才競爭日益激烈，高校的研究計劃也越發的昂貴，這使得企業有更多的機會“入侵”校園。美國大多數的藥劑公司和整個學術部門簽訂了合同，實質上是一種學術壟斷。據美國教育委員會主席Stanley O.Ikenberry研究發現，特別是在醫學教育方面，過去10年，醫學教育的質量和性質、決策者們的戰略性選擇更多的是被市場所左右，而不是從醫學教育發展的長遠目標出發。

With competition for talented people becoming fiercer， the budget of higher institutions of learning for research rose to a new height， giving more opportunities for the enterprises to get into schools. Most of the pharmaceutical companies have signed contracts with the whole academic circle， which is intrinsically a kind of academic monopoly. Stanley O.Ikenberry， president of the Commission of Education of the United States， discovered in his research that it was the market instead of the consideration for a long-term development of the medical science that determined the quality and nature of the medical education， and influenced the strategic choice.